RV 365

A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR , a Multigenic, Recombinant Modified Vaccinia Ankara HIV-1 Vaccine Expressing Env gp 150/Gag/Pol, in HIV-uninfected Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) Plus Poly-ICLC (Hiltonol?) (RV 365 / WRAIR #2006).

Trial Details:

I Completed
Rockefeller University July 01, 2013
MVA-CMDR Gag-Pol, Env E
MVA-CMDR Viral Vector - Pox
USA 33